GSK461364

GSK461364

Catalog Number:
L002369548APE
Mfr. No.:
APE-A8441
Price:
$277
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          GSK461364 is a potent and reversible ATP competitive Plk1 inhibitor. Polo-like kinases (Plk) are a family of serine threonine kinases that are critical regulators of DNA damage response and cell cycle progression.
          In vitro: GSK461364 showed at least 390-fold greater selectivity for Plk1 than for Plk2 and Plk3 and 1,000-fold greater than for 48 other kinases. The drug showed antiproliferative activity against multiple (>120) tumor cell lines and potently inhibited the proliferation of greater than 83% and 91% of these cell lines [1].
          In vivo: Intraperitoneal administration of GSK461364 caused regression or tumor growth delay in different xenograft models. In vivo suppression of Plk1 by using GSK461364 resulted in mitotic arrest with aberrant mitotic figures consisting of monopolar or collapsed mitotic spindles [1].
          Clinical trial: The final recommended phase II dose for GSK461364 was 225 mg administered intravenously. Moreover, GSK461364 was suggested to involve coadministration of prophylactic anticoagulation for further clinical evaluation [1].

      • Properties
        • Alternative Name
          5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide
          CAS Number
          929095-18-1
          Molecular Formula
          C27H28F3N5O2S
          Molecular Weight
          543.6
          Purity
          98.00%
          Solubility
          insoluble in H2O; ≥15.65 mg/mL in EtOH; ≥49.5 mg/mL in DMSO
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Velpurisiva P, Rai P. "Synergistic Action of Gefitinib and GSK41364A Simultaneously Loaded in Ratiometrically-Engineered Polymeric Nanoparticles for Glioblastoma Multiforme." J Clin Med. 2019 Mar 15;8(3). pii: E367. PMID:30875975
          2. Velpurisiva P, Piel BP, et al. "GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)." Bioengineering (Basel). 2018 Oct 9;5(4). pii: E83. PMID:30304810
          3. Higuchi F, Fink AL, et al."PLK1 inhibition targets Myc-activated malignant glioma cells irrespective of mismatch repair deficiency-mediated acquired resistance to temozolomide." Mol Cancer Ther. 2018 Sep 14. pii: molcanther.0177.2018. PMID:30217967

    We Also Recommend

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.